PDSS has rapidly grown, becoming one of the most well attended drug safety conferences in the US, drawing participants from the US, Europe, Latin America and Asia.
Emeryville, CA, (PRWEB) May 31, 2013
Dohmen’s BioSoteria Calls for Abstracts for its Seventh Annual Pacific Drug Safety Summit (PDSS)
September Conference Draws Global Biopharmaceutical Drug Safety and Medical Communications Decision-Makers to San Francisco
Emeryville, CA, May 28, 2013 -- BioSoteria, Drug Safety and Risk Management Specialists, and organizers of the Annual Pacific Drug Safety Summit (PDSS), have launched the PDSS website and now invite abstract submissions for oral presentations for the main conference or pre-conference tutorial at the 7th Annual PDSS. The conference will be held on September 19-20, 2013 at the Hilton San Francisco Airport Bayfront, Burlingame, CA.
“PDSS has rapidly grown, becoming one of the most well attended drug safety conferences in the US, drawing participants from the US, Europe, Latin America and Asia. Our speakers are pharmaceutical/biotechnology industry thought leaders who share a passion for excellence in practice and education, and bring a global perspective to the challenges faced in this dynamic regulatory environment,” said James Buchanan, PharmD, BioSoteria Senior Vice President, Pharmacovigilance and Risk Management. “The breadth and depth of experience among our speakers and attendees makes for a dynamic learning environment and networking opportunity. We invite you to express your interest in providing an oral presentation by submitting an abstract to the PDSS website.”
Sponsored pre-conference tutorials will be held on September 19, 2013 and oral presentations will take place during the main conference on September 20, 2013. Speakers are encouraged to submit an abstract based on their work in the area of pharmacovigilance, risk management, pharmacoepidemiology, medical communications, and/or adverse event intake and reporting. Case studies and examples that demonstrate this year’s theme, “Strategies that Drive Quality in Patient Safety and Operational Efficiency” are of particular interest.
PDSS is held annually in San Francisco, home to the largest cluster of life sciences companies in the United States. This year medical communications and adverse event reporting topics have been added to the agenda, including a discussion about the benefits of integrating safety and medical information operations for seamless communication and operational efficiency.
Previous PDSS Conference Topics:
- Globalization of Pharmacovigilance Practices
- Generic Product Safety Practices
- Patient Reported Outcomes in Clinical Research
- Quality Measures of Patient Safety
- Updates on Pharmacovigilance Regulations in EU, Latin America, and Asia
Previous PDSS Conference Speakers:
- Hugh Tilson, MD, DrPH, Adjunct Professor of Public Health Leadership, Epidemiology, and Health Policy, UNC Gillings School of Global Public Health
- Rebecca Wang, MD, Head of Drug Safety, Roche Global Pharma Development Center, China
- Valerie Simmons, MD, BS, FFPM, Lilly QPPV Executive, Global Patient Safety, Eli Lilly & Co Ltd, UK
- James Cross, PhD; Integrated Safety Risk Manager, Genentech
- Judith Zander, MD; Executive Director, Patient Safety, AstraZeneca
- Paul Coplan, Sc.D, MBA, Senior Director, Risk Management, Global Safety Surveillance and Epidemiology, Wyeth Pharmaceuticals
- Robin Geller, PhD; Director of Risk Management, Global Pharmacovigilance, Baxter Healthcare Corporation
- Catherine Hardalo, MD, VP, Clinical Development, Cadence Pharmaceuticals
- Tobias Peschel, MD, PhD, MBA, VP, Drug Safety & Public Health, Gilead Sciences
- Dorcie McKniff Jasperse, PhD; Executive Director Life Sciences, Raland Technologies
- Lisa Lawrence-Miyasaki, Senior Director, Global Clinical Development & Medical Affairs (GCD&MA) Drug Safety, Santen Inc.
- Mary Ellen O’Banion, RN, Director Drug Safety, Watson Pharmaceuticals
- Lauret Ballsun, RN, Principle, LBC Pharmaceuticals, LLC
- Juliane Mills, MT(ASCP) CLS(NCA), Senior Project Manager, Safety, Epidemiology, Registries, and Risk Management, United BioSource Corporation
- Shelley Gandhi, Director, Pharmacovigilance and Drug Safety; NDA Regulatory Science Ltd., UK
- E. Stewart Geary, Vice President and Deputy Director; Easai Co. Ltd., Tokyo, Japan
- Marisa Fernandes, RN, BSN; Manager, Drug Safety Center Latin America, PRA International
Those interested in providing an oral presentation during the main conference day may submit an abstract for consideration by the PDSS Program Committee at
For those corporate sponsors who wish to host a pre-conference tutorial, please submit your tutorial topic and outline for consideration to Penny Bemus at pbemus(at)dohmen(dot)com or call 636-519-2758.
Submissions are due by June 21, 2013.
Founded in 2007, and acquired by Dohmen in 2012, BioSoteria, serves the outsourcing needs of the pharmaceutical industry. From strategic risk management consulting services and full-service drug safety operational capabilities to world-class award winning pharmacovigilance training and education programs, BioSoteria provides unmatched experience, expertise, and leadership to support your company’s efforts to maximize your product’s benefit-risk profile. For more information and to learn more about BioSoteria’s drug safety services and training programs please visit http://www.biosoteria.com.
About Dohmen: Founded in 1858, Dohmen is a privately-held, Life Science Services Company, focused on creating a more efficient, affordable and accessible healthcare supply system. As the trusted partner to more than 600 Biopharma and Medtech innovators, Dohmen propels start-up, mid-tier and Fortune 500 companies with support services that span the commercialization continuum from pre-approval regulatory consulting to in-home patient services. With a tradition of innovation that spans over 155 years, we’re driven by the desire to reduce cost and complexity within today’s healthcare system, using a progressive model that connects life science companies with the patients they serve.